plasma kallikrein in 1

Plasma kallikrein-IN-1 is a PKK inhibitor with an IC 50 value of 0.5 nM.

Berotralstat (BCX7353) is a second-generation, synthetic, and orally active plasma kallikrein inhibitor with low toxicity. It is highly specific and effectively used in the research of hereditary angioedema (HAE) attacks. Berotralstat functions by inhibiting the enzymatic activity of plasma kallikrein, which is responsible for the release of bradykinin. This blocking mechanism targets the major biologic peptide involved in the promotion of swelling and pain associated with HAE attacks[1][2].

Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].

Kallikrein 能够在血浆和组织中形成激肽释放酶激肽系统（KKS)，分别产生缓激肽和激肽肽。

D-Pro-Phe-Arg-Chloromethylketone是一种抑制剂，它针对凝血因子XII (coagulation factor XII) 和血浆激肽释放酶 (kallikrein)，在血栓形成和炎症过程中具有关键作用。

MDI-2268，作为一种血浆激肽释放酶抑制剂1（PAI-1）的抑制剂，具备显著的抗血栓特性。该化合物主要通过促进纤溶活性来调控血液的凝固与纤溶过程。此外，MDI-2268 在深静脉血栓形成的研究领域中显示出有用的应用潜力。